217 related articles for article (PubMed ID: 8862446)
41. Assessment of resistance induction to cytosine arabinoside following transfer and overexpression of the deoxycytidylate deaminase gene in vitro.
Schröder JK; Seidelmann M; Kirch HC; Seeber S; Schütte J
Leuk Res; 1998 Jul; 22(7):619-24. PubMed ID: 9680112
[TBL] [Abstract][Full Text] [Related]
42. Human cytidine deaminase: a biochemical characterization of its naturally occurring variants.
Micozzi D; Carpi FM; Pucciarelli S; Polzonetti V; Polidori P; Vilar S; Williams B; Costanzi S; Vincenzetti S
Int J Biol Macromol; 2014 Feb; 63():64-74. PubMed ID: 24183806
[TBL] [Abstract][Full Text] [Related]
43. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.
Lee JT; Campbell DO; Satyamurthy N; Czernin J; Radu CG
J Nucl Med; 2012 Feb; 53(2):275-80. PubMed ID: 22302964
[TBL] [Abstract][Full Text] [Related]
44. The interaction of gemcitabine and cytarabine on murine leukemias L1210 or P388 and on human normal and leukemic cell growth in vitro.
Lech-Maranda E; Korycka A; Robak T
Haematologica; 2000 Jun; 85(6):588-94. PubMed ID: 10870114
[TBL] [Abstract][Full Text] [Related]
45. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
[TBL] [Abstract][Full Text] [Related]
46. Characterization of resistance to cytosine arabinoside (Ara-C) in NALM-6 human B leukemia cells.
Kanno S; Hiura T; Ohtake T; Koiwai K; Suzuki H; Ujibe M; Ishikawa M
Clin Chim Acta; 2007 Feb; 377(1-2):144-9. PubMed ID: 17097625
[TBL] [Abstract][Full Text] [Related]
47. Myeloprotection by cytidine deaminase gene transfer in antileukemic therapy.
Lachmann N; Brennig S; Phaltane R; Flasshove M; Dilloo D; Moritz T
Neoplasia; 2013 Mar; 15(3):239-48. PubMed ID: 23479503
[TBL] [Abstract][Full Text] [Related]
48. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
Giovannetti E; Mey V; Loni L; Nannizzi S; Barsanti G; Savarino G; Ricciardi S; Del Tacca M; Danesi R
Pharmacol Res; 2007 Apr; 55(4):343-9. PubMed ID: 17296311
[TBL] [Abstract][Full Text] [Related]
49. APOBEC3 upregulation drives gemcitabine resistance.
Maciejowski J; Mohamed T
Nat Cancer; 2024 Jun; 5(6):818-820. PubMed ID: 38778178
[No Abstract] [Full Text] [Related]
50. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.
Kreis W; Woodcock TM; Gordon CS; Krakoff IH
Cancer Treat Rep; 1977 Oct; 61(7):1347-53. PubMed ID: 589600
[TBL] [Abstract][Full Text] [Related]
51. Tightly regulated 'all-in-one' lentiviral vectors for protection of human hematopoietic cells from anticancer chemotherapy.
Lachmann N; Brennig S; Hillje R; Schermeier H; Phaltane R; Dahlmann J; Gruh I; Heinz N; Schiedlmeier B; Baum C; Moritz T
Gene Ther; 2015 Nov; 22(11):883-92. PubMed ID: 26125609
[TBL] [Abstract][Full Text] [Related]
52. Ara-C metabolism: implications for drug resistance and drug interactions.
Chabner BA; Hande KR; Drake JC
Bull Cancer; 1979; 66(1):89-92. PubMed ID: 420952
[TBL] [Abstract][Full Text] [Related]
53. Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.
Bouffard DY; Laliberté J; Momparler RL
Biochem Pharmacol; 1993 May; 45(9):1857-61. PubMed ID: 8494545
[TBL] [Abstract][Full Text] [Related]
54. Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue.
Galmarini CM; Clarke ML; Santos CL; Jordheim L; Perigaud C; Gosselin G; Cros E; Mackey JR; Dumontet C
Int J Cancer; 2003 Oct; 107(1):149-54. PubMed ID: 12925971
[TBL] [Abstract][Full Text] [Related]
55. Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement.
Santini V; D'Ippolito G; Bernabei PA; Zoccolante A; Ermini A; Rossi-Ferrini P
Leuk Res; 1996 Jan; 20(1):37-45. PubMed ID: 8632676
[TBL] [Abstract][Full Text] [Related]
56. Creation of zebularine-resistant human cytidine deaminase mutants to enhance the chemoprotection of hematopoietic stem cells.
Ruan H; Qiu S; Beard BC; Black ME
Protein Eng Des Sel; 2016 Dec; 29(12):573-582. PubMed ID: 27160178
[TBL] [Abstract][Full Text] [Related]
57. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome.
Taub JW; Huang X; Ge Y; Dutcher JA; Stout ML; Mohammad RM; Ravindranath Y; Matherly LH
Cancer Res; 2000 Nov; 60(22):6421-6. PubMed ID: 11103808
[TBL] [Abstract][Full Text] [Related]
58. Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels.
Funamizu N; Lacy CR; Fujita K; Furukawa K; Misawa T; Yanaga K; Manome Y
PLoS One; 2012; 7(5):e37424. PubMed ID: 22616006
[TBL] [Abstract][Full Text] [Related]
59. Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells.
Takemura H; Urasaki Y; Yoshida A; Fukushima T; Ueda T
Cancer Res; 2001 Jan; 61(1):172-7. PubMed ID: 11196156
[TBL] [Abstract][Full Text] [Related]
60. Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment.
Peters GJ; Honeywell RJ; Maulandi M; Giovannetti E; Losekoot N; Etienne-Grimaldi MC; Milano G; Serdjebi C; Ciccolini J;
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):403-12. PubMed ID: 24940698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
